AM2020-Willmer-ID27

AM2020-Willmer-ID27

Welcome to Laser2020Подробнее

Welcome to Laser2020

ILCA 7 World Championships 2021 – Day 2Подробнее

ILCA 7 World Championships 2021 – Day 2

Professor Rajiv Khanna - BV-reactive cytotoxic T-cell therapy in MSПодробнее

Professor Rajiv Khanna - BV-reactive cytotoxic T-cell therapy in MS

Day 2: Movement Festival At Home MDW 2020 | @beatport LiveПодробнее

Day 2: Movement Festival At Home MDW 2020 | @beatport Live

ATA3219, ATA3271 & ATA188: T-Cell immunotherapy products in developmentПодробнее

ATA3219, ATA3271 & ATA188: T-Cell immunotherapy products in development

Admn DJ set - #MovementAtHome MDW 2020 | @beatport LiveПодробнее

Admn DJ set - #MovementAtHome MDW 2020 | @beatport Live

VID 20240917 123201 VI 70Подробнее

VID 20240917 123201 VI 70

MacArthur Foundation 100&Change - William Metcalf & Martin Burke (Extended)Подробнее

MacArthur Foundation 100&Change - William Metcalf & Martin Burke (Extended)

Day 2 2nd Invest in ME Research International ME Conference 2007 Dr Ian Gibson & Sarah VeroПодробнее

Day 2 2nd Invest in ME Research International ME Conference 2007 Dr Ian Gibson & Sarah Vero

МиВвФ 10 20211105 Ахмеров дистПодробнее

МиВвФ 10 20211105 Ахмеров дист

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MSПодробнее

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS

Willian Anthony Jason SmithПодробнее

Willian Anthony Jason Smith

IDoR 2014 - ECR On Demand: NH 7 'The human connectome' (A-158, M.P. van den Heuvel)Подробнее

IDoR 2014 - ECR On Demand: NH 7 'The human connectome' (A-158, M.P. van den Heuvel)

Learning EPIGENETICS (Episode 6): Open Label Placebo EffectПодробнее

Learning EPIGENETICS (Episode 6): Open Label Placebo Effect

Characterization of ATA188: an off-the-shelf therapy for MSПодробнее

Characterization of ATA188: an off-the-shelf therapy for MS

ATA188: an allogeneic EBV-specific T cell therapy for progressive MSПодробнее

ATA188: an allogeneic EBV-specific T cell therapy for progressive MS

Anti-EBV trial shows promise in Progressive MSПодробнее

Anti-EBV trial shows promise in Progressive MS